Portal de Periódicos da CAPES

A new cancer diagnostic system based on a CDK profiling technology

2005; Elsevier BV; Volume: 1741; Issue: 3 Linguagem: Inglês

10.1016/j.bbadis.2005.06.001

1879-260X

Hideki Ishihara, Tomokazu Yoshida, Yuko Kawasaki, Hironori Kobayashi, Masatoshi Yamasaki, Satoshi Nakayama, Erika Miki, Kei-ichiro Shohmi, Tomoko Matsushima, Sachiyo Tada, Yasuhiro Torikoshi, M Morita, Shigeyuki Tamura, Yoko Hino, Jun Kamiyama, Yoshihiro Sowa, Yasunari Tsuchihashi, Hisakazu Yamagishi, Toshiyuki Sakai,

RNA modifications and cancer

A series of molecular pathological investigations of the molecules that stimulate the cyclin dependent kinases (CDK1, 2, 4, and 6) have led to enormous accumulation of knowledge of the clinical significance of these molecules for cancer diagnosis. However, the molecules have yet to be applied to clinical cancer diagnosis, as there is no available technology for application of the knowledge in a clinical setting. We hypothesized that the direct measurement of CDK activities and expressions (CDK profiling) might produce clinically relevant values for the diagnosis. This study investigated the clinical relevance of CDK profiling in gastrointestinal carcinoma tissues by using originally developed expression and activity analysis methods. We have established novel methods and an apparatus for analyzing the expression and activities of the CDK molecules in lysate of tumor tissue in a clinical setting, and examined 30 surgically dissected gastrointestinal carcinomas and corresponding normal mucosal specimens. We demonstrate here that remarkably elevated CDK2 activity is evident in more than 70% of carcinoma tissues. Moreover, a G1-CDK activity profiling accurately mirrored the differences in proliferation between tumor and normal colonic tissues. Our results suggest that CDK profiling is a potent molecular–clinical approach to complement the conventional pathological diagnosis, and to further assist in the individualized medications.